Antibody-drug conjugates for primary brain tumors

Antibody-drug conjugates (ADCs) enable targeted delivery of cytotoxic or immunomodulatory payloads to cancer cells while relatively sparing healthy tissues. Interest in using ADCs for the treatment of primary brain tumors is growing, as these are frequently infiltrative with tumor cells coexisting with healthy glial and neural tissue. Emerging clinical and translational data from studies of ADCs in primary brain tumors and brain metastases provide evidence of blood-brain barrier penetration and